756 related articles for article (PubMed ID: 37143162)
1. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
[TBL] [Abstract][Full Text] [Related]
2. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
3. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.
Smart R; Kim JY; Kennedy S; Tang L; Allen L; Crane D; Mack A; Mohamoud S; Pauly N; Perez R; Donohue J
J Subst Abuse Treat; 2023 Jan; 144():108921. PubMed ID: 36327615
[TBL] [Abstract][Full Text] [Related]
4. Impact of an intervention to implement provision of opioid use disorder medication among patients with and without co-occurring substance use disorders.
Frost MC; Malte CA; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
J Subst Use Addict Treat; 2023 Dec; 155():209175. PubMed ID: 37751798
[TBL] [Abstract][Full Text] [Related]
5. Associations Between Distinct Co-occurring Substance Use Disorders and Receipt of Medications for Opioid Use Disorder in the Veterans Health Administration.
Frost MC; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
J Addict Med; 2023 May-Jun 01; 17(3):278-285. PubMed ID: 37267168
[TBL] [Abstract][Full Text] [Related]
6. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
Burke KN; Krawczyk N; Li Y; Byrne L; Desai IK; Bandara S; Feder KA
J Subst Use Addict Treat; 2024 Jul; 162():209351. PubMed ID: 38499248
[TBL] [Abstract][Full Text] [Related]
7. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
[TBL] [Abstract][Full Text] [Related]
9. Barriers to Assessing and Treating Trauma in Primary Care and Opportunities for Improvement: Perspectives from Prescribers of Medications for Opioid Use Disorder.
Winiker AK; Heidari O; Pollock S; Sodder S; Tobin KE
Subst Use Misuse; 2023; 58(13):1651-1659. PubMed ID: 37495397
[No Abstract] [Full Text] [Related]
10. A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.
Taylor EN; Timko C; Binswanger IA; Harris AHS; Stimmel M; Smelson D; Finlay AK
Subst Abus; 2022; 43(1):556-563. PubMed ID: 34586978
[No Abstract] [Full Text] [Related]
11. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
12. Implementation of a pharmacist care manager model to expand availability of medications for opioid use disorder.
DeRonne BM; Wong KR; Schultz E; Jones E; Krebs EE
Am J Health Syst Pharm; 2021 Feb; 78(4):354-359. PubMed ID: 33326564
[TBL] [Abstract][Full Text] [Related]
13. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
Mauro PM; Gutkind S; Annunziato EM; Samples H
JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
[TBL] [Abstract][Full Text] [Related]
14. Clinical leaders and providers' perspectives on delivering medications for the treatment of opioid use disorder in Veteran Affairs' facilities.
Hawkins EJ; Danner AN; Malte CA; Blanchard BE; Williams EC; Hagedorn HJ; Gordon AJ; Drexler K; Burden JL; Knoeppel J; Lott A; Sayre GG; Midboe AM; Saxon AJ
Addict Sci Clin Pract; 2021 Sep; 16(1):55. PubMed ID: 34488892
[TBL] [Abstract][Full Text] [Related]
15. Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators.
O'Grady MA; Elkington KS; Robson G; Achebe IY; Williams AR; Cohall AT; Cohall R; Christofferson M; Garcia A; Ramsey KS; Lincourt P; Tross S
Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):12. PubMed ID: 38287329
[TBL] [Abstract][Full Text] [Related]
16. Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities.
Wyse JJ; Shull S; Lindner S; Morasco BJ; Gordon AJ; Carlson KF; Korthuis PT; Ono SS; Liberto JG; Lovejoy TI
J Gen Intern Med; 2023 Jun; 38(8):1871-1876. PubMed ID: 36690913
[TBL] [Abstract][Full Text] [Related]
17. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
[TBL] [Abstract][Full Text] [Related]
18. The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.
Frost MC; Lampert H; Tsui JI; Iles-Shih MD; Williams EC
Addict Sci Clin Pract; 2021 Oct; 16(1):62. PubMed ID: 34635170
[TBL] [Abstract][Full Text] [Related]
19. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
[TBL] [Abstract][Full Text] [Related]
20. Co-occurring implementation strategies: The effects of academic detailing for opioid use disorder campaign on the advancing pharmacological treatments for opioid use disorder (ADaPT-OUD) study.
Miller WA; Gordon AJ; Clothier BA; Ackland PE; Bounthavong M; Garcia C; Kenny ME; Noorbaloochi S; Hagedorn HJ
Implement Res Pract; 2023; 4():26334895231199463. PubMed ID: 37790176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
